CD274 and gastric cancer: Based on the positive findings of the KEYNOTE-059 study cohort, the FDA has granted approval for the use of pabolizumab in patients with PD-L1-positive gastric cancer and gastroesophageal junction cancer (GEJC) who have not responded to previous treatment39.